中西医结合治疗常见肝胆胰疾病的现状与展望

王融冰; 孙凤霞

doi:10.3969/j.issn.1001-5256.2018.04.001

中西医结合治疗常见肝胆胰疾病的现状与展望

DOI: 10.3969/j.issn.1001-5256.2018.04.001

1. 首都医科大学附属北京地坛医院
2. 首都医科大学附属北京中医医院

基金项目:

2016年国家中医药管理局名医工作室项目；

详细信息

中图分类号: R57
计量
- 文章访问数: 2236
- HTML全文浏览量: 9
- PDF下载量: 476
- 被引次数: 0
出版历程
- 出版日期: 2018-04-20

Current status and perspectives of integrated traditional Chinese and Western medicine therapy for common hepatobiliary and pancreatic diseases

Beijing Ditan Hospital, Capital Medical University

Research funding:

摘要

摘要: 目前中西医结合诊疗形式主要是中医药治疗或中药与西药联合使用两种状态,均用现代诊断和疗效评价,虽缺乏理论突破,但在临床、科研实践中有了更多共识和创新。归纳和评述近10年来常见肝胆胰疾病治疗领域的临床、科研现状,采纳临床有明确疾病诊断且经过重大科研课题或有循证医学证据的疗效、成果,以及在核心期刊发表的论文。力求客观反映当前中西医结合治疗肝胆胰疾病的优效和研究热点,以期对本领域临床和科研有所启发。
- 肝疾病 /
- 胆道疾病 /
- 胰腺疾病 /
- 中西医结合疗法 /
- 述评
Abstract: At present, the diagnosis and treatment with integrated traditional Chinese and Western medicine takes the form of traditional Chinese medicine treatment or the combination of traditional Chinese medicine and Western medicine, with the application of modern diagnostic and therapeutic evaluation methods.Although there lacks theoretical breakthrough, more and more consensus statements and innovations have been accumulated in clinical practice and scientific research.This article introduces the current status of clinical practice and research in the treatment of common hepatobiliary and pancreatic diseases in the past 10 years and collects the articles with a definite diagnosis, major scientific research projects, and evidence of evidence-based medicine which are published in core journals.We aim to objectively reflect the advantages and effects of integrated traditional Chinese and Western medicine therapy for hepatobiliary and pancreatic diseases, in order to provide new inspirations for clinical practice and scientific research in this field.
- liver diseases /
- biliary tract diseases /
- pancreatic diseases /
- TCM WM therapy /
- editorial

HTML全文

参考文献(28)

[1]CHEN WLK, EDINGTON C, SUTER E, et al.Integrated gut/liver microphysiological systems elucidates inflammatory inter-tissue crosstalk[J].Biotechnol Bioeng, 2017, 114 (11) :2648-2659.

[2]CAROTT S, GUARINO MP, VESPASIANI-GENTILUCCI U, et al.Starring role of toll-like receptor-4 activation in the gut-liver axis[J].World J Gastrointest Pathophysiol, 2015, 6 (4) :99-109.

[3]TLASKALOVA-HOGENOVA H, STEPANKOVA R, KOZAKOVA H, et al.The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer:contribution of germ-free and gnotobiotic animal models of human diseases[J].Cell Mol Immunol, 2011, 8 (2) :110-120.

[4]SUN WJ, ZHANG B, LI DK, et al.Development status and clinical application progress of probiotic preparations[J].Chin Hosp Pharm J, 2015, 35 (9) :850-857. (in Chinese) 孙雯娟, 张波, 李大魁, 等.益生菌制剂的发展现状与临床应用进展[J].中国医院药学杂志, 2015, 35 (9) :850-857.

[5]NETEA-MAIER RT, PLANTINGA TS, van de VEERDONK FL, et al.Modulation of inflammation by autophagy:consequences for human disease[J].Autophagy, 2016, 12 (2) :245-260.

[6]YAN XW, GUO JH, YU HH, et al.Observation on body weight, blood pressure and blood glucose of six subjects and analysis on Bigu regimen[J].China J Tradit Chin Med Pharma, 2016, 31 (2) :627-629. (in Chinese) 燕晓雯, 郭建红, 俞海虹, 等.6名辟谷受试者体质量、血压、血糖观察及辟谷养生技术分析[J].中华中医药杂志, 2016, 31 (2) :627-629.

[7]YANG L, ZHANG D.Summary of dihydroartemisinin and its application for the treatment of lupus erythematosus[J].Chin Sci Bull, 2017, 62 (18) :2007-2012. (in Chinese) 杨岚, 张东.双氢青蒿素及其红斑狼疮新适应症研究概述[J].科学通报, 2017, 62 (18) :2007-2012.

[8]AVASARALA S, ZHANG FF, LIU GL, et al.Curcumin modulates the inflammatory response and inhibits subsequent fibrosis in a mouse model of viral-induced acute respiratory distress syndrome[J].PLo S One, 2013, 8 (2) :e57285.

[9]AHN JK, KIM S, HWANG J, et al.Metabolomic elucidation of the effects of curcumin on fibroblast-like synoviocytes in rheumatoid arthritis[J].PLo S One, 2015, 10 (12) :e0145539.

[10]SHAKIBAEI M, MOBASHERI A, LUEDERS C, et al.Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-κB and src protein kinase signaling pathways[J].PLo S One, 2013, 8 (2) :e57218.

[11]CHUENGSAMARN S, RATTANAMONGKOLGUL S, LUECHAPUDIPORN R, et al.Curcumin extract for prevention of type 2 diabetes[J].Diabetes Care, 2012, 35 (11) :2121-2127.

[12]LUO TS, LI HW, LIU ZW, et al.Advances in studies on extraction, separation, and pharmacological action of curcumin[J].Drugs Clinic, 2011, 26 (2) :102-107. (in Chinese) 罗廷顺, 李洪文, 刘正文, 等.姜黄素的提取分离与药理作用研究进展[J].现代药物与临床, 2011, 26 (2) :102-107.

[13]XUAN SY, YUAN C, LU LL, et al.Research advances in susceptibility genes and their role in the pathogenesis of nonalcoholic fatty liver disease[J].J Clin Hepatol, 2016, 32 (3) :446-452. (in Chinese) 宣世英, 袁晨, 芦琳琳, 等.非酒精性脂肪性肝病相关易感基因及其在发病机制中的作用[J].临床肝胆病杂志, 2016, 32 (3) :446-452.

[14]CHEN Q, RONG P, XU D.Rab8a deficiency in skeletal muscle causes hyperlipidemia and hepatosteatosis via impairment of muscle lipid uptake and storage[J].Diabetes, 2017, 66 (9) :2387-2399.

[15] ZHANG WW.Study on the regulation and function of the expression of Ng BR in the liver——a new mechanism of atorvastatin on the improvement of liver steatosis[D].Nanjing:Nankai Univ, 2016. (in Chinese) 张雯雯.肝脏Ng BR的表达调控与功能研究——阿托伐他汀改善肝脏脂肪变性作用新机制研究[D].南京:南开大学, 2016.

[16]Branch of Gastrointestinal Diseases, China Association of Chinese Medicine.Expert consensus on TCM diagnosis and treatment of nonalcoholic fatty liver disease (2017) [J].J Clin Hepatol, 2017, 33 (12) :2270-2274. (in Chinese) 中华中医药学会脾胃病分会.非酒精性脂肪性肝病中医诊疗专家共识意见 (2017) [J].临床肝胆病杂志, 2017, 33 (12) :2270-2274.

[17]ZHOU AF.Study on anti-obesity effects of turmeric and drug partner of turmeric-rhubarb[J].J Wenzhou Univ:Natural Sci, 2010, 31 (4) :16-20. (in Chinese) 周爱芬.姜黄及姜黄-大黄药的减肥作用[J].温州大学学报:自然科学版, 2010, 31 (4) :16-20.

[18]XIA MF.Quantitative diagnosis and serological related study of nonalcoholic fatty liver disease and metabolic syndrome[D].Shanghai:Fudan Univ, 2012. (in Chinese) 夏明锋.非酒精性脂肪性肝病与代谢综合征的定量诊断和血清学相关指标研究[D].上海:复旦大学, 2012.

[19]JANSEN PL.Non-alcoholic steatohepatitis[J].Eur J Gastroenterol Hepatol, 2004, 16:1079-1085.

[20]FENG Y, CHEUNG KF, WANG N, et al.Chinese medicines as a resource for liver fibrosis treatment[J].Chin Med, 2009, 4:16.

[21] WANG GQ.The present situation and prospect of anti-fibrosis therapy[C].The eighteenth National Academic Conference on viral hepatitis and liver disease of the Chinese Medical Association.Wuhan, 2017. (in Chinese) 王贵强.抗纤维化治疗的现状与展望[C].中华医学会第十八次全国病毒性肝炎及肝病学术会议.武汉, 2017.

[22]LU W, GAO YH, WANG ZZ, et al.Effects of Anluohuaxianwan on transforming growth factor-β1 and related signaling pathways in rats with carbon liverfibrosis[J].Chin J Hepatol, 2017, 25 (4) :257-262. (in Chinese) 卢玮, 高玉华, 王珍子, 等.安络化纤丸对肝纤维化大鼠转化生长因子β1及相应信号通路的影响[J].中华肝脏病杂志, 2017, 25 (4) :257-262.

[23]ZHANG BF, CHEN ML, WANG YP, et al.Influence of blueberry on TGF-β1/Smads signal transduction in liver tissues of the rats with liver fibrosis[J].Infect Dis Info, 2010, 23 (3) :148-153. (in Chinese) 张宝芳, 程明亮, 王豫萍, 等.蓝莓对大鼠肝纤维化TGF-β_1/Smads信号通路的影响[J].传染病信息, 2010, 23 (3) :148-153.

[24]YUAN S, FU ZQ.To observe the curative effect of Dachaihu Decoction in the treatment of mild acute pancreatitis[J].Zhejiang J Tradit Chin Med, 2016, 51 (10) :744-745. (in Chinese) 袁帅, 傅志泉.大柴胡汤治疗轻症急性胰腺炎疗效观察[J].浙江中医杂志, 2016, 51 (10) :744-745.

[25]WANG J.Chinese medicine treatment for acute abdomen[J].J Emerg Tradit Chin Med, 2011, 20 (1) :161-162. (in Chinese) 王建.急腹症的中医治疗[J].中国中医急症, 2011, 20 (1) :161-162.

[26] HUANG XY.TCM internal medicine emergency syndrome[M].Beijing:People's Health Press, 2000:15-35. (in Chinese) 黄星垣.中医内科急症证治[M].北京:人民卫生出版社, 2000:15-35.

[27]ZENG ZH, ZENG MH, ZHOU Y.Expression of COX-2 in nonalcoholic fatty liver rats and study on intervention effect of acu-point catgut embedding therapy on backoshu points[J].China J Tradit Chin Med Pharma, 2015, 30 (9) :3326-3328. (in Chinese) 曾志华, 曾明慧, 周滢.非酒精性脂肪肝模型大鼠环氧合酶2的表达及背俞穴穴位埋线的干预作用研究[J].中华中医药杂志, 2015, 30 (9) :3326-3328.

[28]HE C, SHI WQ, YANG YH.Clinical efficacy research in treating liver cirrhosis patients with portal hypertension by Xiaogu plaster combined with medical instrument on hepatic diseases[J].Chin Arch Tradit Chin Med, 2016, 34 (2) :499-502. (in Chinese) 何创, 施维群, 杨永和.“消臌贴膏”联合肝病治疗仪治疗肝硬化门脉高压疗效观察[J].中华中医药学刊, 2016, 34 (2) :499-502.

施引文献

资源附件(0)

访问统计